TYRA today
$20.02-$0.95 (-4.53%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourBearish
1 hourStrong Bearish
15 minLeaning Bullish
5 minSymmetric Triangle
Daily trend turns up above $26.96
Key levels
Resistance$21.94
Resistance$20.32
Support$18.25
Support$16.05
Latest news & SEC filings
AnalystWedbush keeps Outperform rating on Tyra Biosciences, lifts target to $57
AnalystHC Wainwright keeps Buy rating on Tyra Biosciences, cuts price target to $27
All TYRA news →About Tyra Biosciences
Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines targeting FGFR biology for oncology and genetically defined conditions. Its lead oral candidate, dabogratinib, is in mid-stage trials for urothelial cancers and the skeletal condition achondroplasia, with additional candidates in early trials for liver cancer and bile duct cancer. The company's SNÅP platform supports its wholly owned pipeline, and it operates primarily in the United States.
Based on the company's 10-K filed Mar 2, 2026.
Nasdaq · Healthcare
Tyra Biosciences, Inc. (TYRA)
What Is the Price Target for TYRA?
SEPT Low Target
$29.00
SEPT Mid Target
$43.50
SEPT High Target
$54.00
Analyst Consensus
$43.50
Is TYRA a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TYRA.
Start Free Trial →Is TYRA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$36.09
12
Moat Score
NONE
1/9
Piotroski Score
31.7
Altman Z-Score
What Is Smart Money Doing with TYRA?
Insider Signal
SELLING
1 buys / 5 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Harris Todd | director officer | Buy | 864 | $8K | Sep 15, 2026 |
| Fuhrman Alan | officer | Buy | 951 | $9K | Sep 15, 2026 |
| Verjee Rehan | director | Buy | 971 | $20K | Sep 9, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TYRA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-33.11%
FCF Growth YoY
-35.3%
Revenue Trend
UNKNOWN
Dark Pool Trades for TYRA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TYRA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:37 | $20.97 | 2,034 | $$43K | BUY |
| 21:00:37 | $20.97 | 2,804 | $$59K | BUY |
| 21:00:37 | $20.97 | 2,097 | $$44K | BUY |
| 21:00:37 | $20.97 | 1,373 | $$29K | BUY |
| 20:59:41 | $20.95 | 1,901 | $$40K | MIDPOINT |
5 dark pool trades shown · $$214K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Tyra Biosciences, Inc. (TYRA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TYRA — frequently asked questions
What is TYRA stock price today?
Tyra Biosciences, Inc. (TYRA) is at $20.02, down 4.53% (-$0.95) at the Nov 12, 2026 close.
Why is TYRA stock moving today?
Latest TYRA news — Nov 11, 2026: Wedbush keeps Outperform rating on Tyra Biosciences, lifts target to $57 · Nov 11, 2026: HC Wainwright keeps Buy rating on Tyra Biosciences, cuts price target to $27
Why did TYRA stock move on Nov 10, 2026?
Tyra Biosciences reported Q3 2026 results, posting a wider-than-expected quarterly loss of $0.74 per share versus the $0.69 shortfall analysts had projected. The company also filed a Form 8-K disclosing a major corporate event alongside its earnings update.
What is the TYRA price target?
The average analyst price target for TYRA is $43.50, ranging from $29 to $54, based on 6 analysts. Latest: HC Wainwright & Co. maintains on Sep 22, 2026.
What do analysts rate TYRA?
Analyst ratings for TYRA: 0 Buy, 11 Hold, 0 Sell — consensus Hold.
Did TYRA beat earnings?
TYRA last reported on Nov 11, 2026: EPS -$0.74 vs -$0.69 expected — a miss of 7.2%.
Does TYRA pay a dividend?
TYRA does not currently pay a dividend.
What are TYRA support and resistance levels?
Support: $18.25, $16.05, $14.77. Resistance: $20.32, $21.94, $24.17.
What are insiders doing with TYRA?
Insider activity: SELLING, 1 buys and 5 sells in the last 90 days.
What is the latest news on TYRA?
Nov 11, 2026: Wedbush keeps Outperform rating on Tyra Biosciences, lifts target to $57 · Nov 11, 2026: HC Wainwright keeps Buy rating on Tyra Biosciences, cuts price target to $27